Atrium Therapeutics, Inc. (RNA)
Atrium Therapeutics, Inc. (RNA) Insider Trading
Directors, officers and holders of more than 10% of RNA report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 279 transactions on file: 0 with code P, 18 with code S and 32 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Younis Husam | Chief Scientific Officer | F Tax Payment | 11,216 | $8.95 | $100,383 |
| Sep 18, 2026 | Winslow Brendan R. | Chief Financial Officer | F Tax Payment | 6,742 | $8.95 | $60,341 |
| Sep 18, 2026 | Boyce Sarah | Director | F Tax Payment | 126,418 | $8.95 | $1,131,441 |
| Sep 18, 2026 | Gallagher Kathleen P. | See Remarks | F Tax Payment | 11,632 | $8.95 | $104,106 |
| Sep 18, 2026 | Flanagan W. Michael | Director | F Tax Payment | 22,812 | $8.95 | $204,167 |
| Sep 18, 2026 | Kenney Stephanie | See Remarks | F Tax Payment | 2,375 | $8.95 | $21,256 |
| Sep 18, 2026 | Hughes Steven George | Chief Medical Officer | F Tax Payment | 21,459 | $8.95 | $192,058 |
| Sep 18, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | F Tax Payment | 8,320 | $8.95 | $74,464 |
| Apr 20, 2026 | Gallagher Kathleen P. | See Remarks | A Award | 205,000 | Not measured | Not measured |
| Apr 20, 2026 | Younis Husam | Chief Scientific Officer | A Award | 60,000 | Not measured | Not measured |
| Apr 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A Award | 30,000 | Not measured | Not measured |
| Apr 20, 2026 | Hughes Steven George | Chief Medical Officer | A Award | 30,000 | Not measured | Not measured |
| Apr 20, 2026 | Kenney Stephanie | See Remarks | A Award | 60,000 | Not measured | Not measured |
| Apr 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A Award | 60,000 | Not measured | Not measured |
| Apr 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A Award | 30,000 | Not measured | Not measured |
| Apr 20, 2026 | Kenney Stephanie | See Remarks | A Award | 30,000 | Not measured | Not measured |
| Apr 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A Award | 60,000 | Not measured | Not measured |
| Apr 20, 2026 | Younis Husam | Chief Scientific Officer | A Award | 30,000 | Not measured | Not measured |
| Apr 20, 2026 | Gallagher Kathleen P. | See Remarks | A Award | 102,500 | Not measured | Not measured |
| Apr 20, 2026 | Hughes Steven George | Chief Medical Officer | A Award | 60,000 | Not measured | Not measured |
| Feb 27, 2026 | WILSON TROY EDWARD | Director | A Award | 20,000 | Not measured | Not measured |
| Feb 27, 2026 | Flanagan W. Michael | Director | A Award | 20,000 | Not measured | Not measured |
| Feb 27, 2026 | BOESS CARSTEN | Director | A Award | 20,000 | Not measured | Not measured |
| Feb 27, 2026 | Boyce Sarah | Director | A Award | 20,000 | Not measured | Not measured |
| Feb 27, 2026 | Skerjanec Simona | Director | A Award | 20,000 | Not measured | Not measured |
| Jan 21, 2026 | Hughes Steven George | Chief Medical Officer | S Sale | 2,017 | $72.45 | $146,132 |
| Jan 21, 2026 | Flanagan W. Michael | Chief Scientific Officer | S Sale | 2,558 | $72.45 | $185,327 |
| Jan 21, 2026 | Boyce Sarah | President and CEO | S Sale | 6,394 | $72.45 | $463,245 |
| Jan 21, 2026 | Hughes Steven George | Chief Medical Officer | S Sale | 2,878 | $72.45 | $208,511 |
| Jan 21, 2026 | Boyce Sarah | President and CEO | S Sale | 7,993 | $72.45 | $579,093 |
| Jan 21, 2026 | Flanagan W. Michael | Chief Scientific Officer | S Sale | 3,976 | $72.45 | $288,061 |
| Jan 21, 2026 | MacLean Michael F | Chief Financial Officer | S Sale | 1,807 | $72.45 | $130,917 |
| Jan 21, 2026 | MacLean Michael F | Chief Financial Officer | S Sale | 2,735 | $72.45 | $198,151 |
| Jan 21, 2026 | LEVIN ARTHUR A | Director | S Sale | 1,758 | $72.45 | $127,367 |
| Jan 21, 2026 | McCarthy Teresa | Chief Human Resources Officer | S Sale | 1,453 | $72.45 | $105,270 |
| Jan 21, 2026 | McCarthy Teresa | Chief Human Resources Officer | S Sale | 1,476 | $72.45 | $106,936 |
| Jan 7, 2026 | Flanagan W. Michael | Chief Scientific Officer | S Sale | 2,373 | $72.23 | $171,402 |
| Jan 7, 2026 | Moriarty John B | Chief Legal Officer | S Sale | 2,374 | $72.23 | $171,474 |
| Jan 7, 2026 | MacLean Michael F | Chief Financial Officer | S Sale | 1,974 | $72.23 | $142,582 |
| Jan 7, 2026 | McCarthy Teresa | Chief Human Resources Officer | S Sale | 1,965 | $72.23 | $141,932 |
| Jan 7, 2026 | Hughes Steven George | Chief Medical Officer | S Sale | 2,373 | $72.23 | $171,402 |
| Jan 7, 2026 | Calderaro Charles III | Chief Technical Officer | S Sale | 3,727 | $72.23 | $269,201 |
| Jan 7, 2026 | Boyce Sarah | President and CEO | S Sale | 8,576 | $72.23 | $619,444 |
| Dec 19, 2025 | LEVIN ARTHUR A | Director | G Gift | 1,330 | Not measured | Not measured |
| Dec 18, 2025 | Boyce Sarah | President and CEO | G Gift | 29,159 | Not measured | Not measured |
| Dec 17, 2025 | Calderaro Charles III | Chief Technical Officer | A Award | 23,250 | Not measured | Not measured |
| Dec 17, 2025 | Calderaro Charles III | Chief Technical Officer | F Tax Payment | 9,726 | $71.87 | $699,008 |
| Dec 17, 2025 | Flanagan W. Michael | Chief Scientific Officer | F Tax Payment | 13,695 | $71.87 | $984,260 |
| Dec 17, 2025 | Flanagan W. Michael | Chief Scientific Officer | A Award | 27,500 | Not measured | Not measured |
| Dec 17, 2025 | Mosbrooker Eric | Chief Commercial Officer | A Award | 72,000 | Not measured | Not measured |
The full Form 4 history is on the RNA company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.